Latest News and Press Releases

Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 19-13/ København, 18. juli 2013   Den 17. juli 2013 tildelte Europa-Kommissionen Orphan Drug-status for belinostat til behandling af maligne...

Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 18-13 / København, 17. juni 2013 Topotarget offentliggør, at positive subtype data på angioimmunoblastisk T-celle lymfekræft (AITL) fra BELIEFstudiet...

To NASDAQ OMX Copenhagen A/S Announcement no. 18-13 / Copenhagen, June 17, 2013 Topotarget announces that positive subtype data on angioimmunoblastic T-cell lymphoma (AITL) from the BELIEF trial...

Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 17-13 / København, 3. juni 2013 Topotarget annoncerede i dag positive resultater fra BELIEF-studiet, et pivotalt, enkeltarms-studie af belinostat i...

To NASDAQ OMX Copenhagen A/S Announcement no. 17-13 / Copenhagen, June 3, 2013 Topotarget today announced positive results from the BELIEF trial, a pivotal, single-arm study of belinostat in...

Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 16-13 / København, 16. maj 2013 Topotarget offentliggør at kliniske belinostat resuméer den 15. maj 2013 kl. 18.00 EDT er blevet offentliggjort i...

To NASDAQ OMX Copenhagen A/S Announcement No. 16-13 / Copenhagen, May 16, 2013 Topotarget announces that abstracts on belinostat clinical data were released for ASCO 2013 on May 15, 2013 at 6.00...

To NASDAQ OMX Copenhagen A/S Announcement No. 15-13 / Copenhagen, May 16, 2013 Topotarget announces that an abstract containing positive final data from the registrational BELIEF study with...

Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 15-13 / København, 16. maj 2013 Topotarget meddeler hermed, at der er frigivet et videnskabeligt resumé med positive endelige data fra...

To NASDAQ OMX Copenhagen A/S Investor News No. 06-13 / Copenhagen, May 14, 2013 Topotarget sends out invitation for shareholder meetings in Copenhagen (Tuesday, June 11, 2013) and Aarhus...